Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

Coronary Artery Disease Clinical Trial

Official title:

A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01384747
• Other study ID #: CVRF2011-03
• Status: Terminated
• Phase: Phase 4
• Start date: July 2011
• Est. completion date: March 2018

Study information

• Verified date: June 2018
• Source: CardioVascular Research Foundation, Korea
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• Fimasartan will be more beneficial in stabilizing the plaque vulnerability compared to control group in deferred coronary lesions.

• Fimasartan will be more beneficial in reducing total plaque volume compared to control group in deferred coronary lesions.

• Fimasartan will be more beneficial in reducing functional impairment of stenotic lesions (assessed by FFR:Fractional Flow Reserve) in deferred coronary lesions.

Description:

Prospective, double-blind, randomized clinical study with enrollment of patients over at least 18 years of age who require coronary angiography for a clinical indication with hypertension defined as systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg. Inclusion requires at least one deferred coronary lesion with 1) visually-estimated angiographic %diameter stenosis 20-50% or 2) %diameter stenosis >50% without any evidence of inducible ischemia. The target vessel for IVUS interrogation must not have undergone angioplasty (deferred lesion) nor have more than 50% luminal narrowing throughout a target segment. Patients meeting inclusion criteria without any exclusion criteria will be randomized 1:1 (Fimasartan 60-120 mg vs placebo). All subjects will be followed up at 1 year for serial VH-IVUS and conventional IVUS evaluation. Also, OCT sub-study will be performed in selected patients with lesions at least 20 mm distally located from coronary ostium. All patients will be blindly assigned to control and Fimasartan once daily as 1:1 ratio and are prescribed for 1year.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 186
• Est. completion date: March 2018
• Est. primary completion date: March 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 84 Years

Eligibility

Inclusion Criteria:

1. Hypertensive patients (systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg) or medically treated hypertension with normal blood pressure who undergo coronary angiography with clinical indications

2. 18 < Age < 85

3. Patient who has received informed consent

4. at least one deferred coronary lesion with 1) visually-estimated angiographic %diameter stenosis 20-50% or 2) %diameter stenosis >50% without any evidence of inducible ischemia (FFR = 0.8 or negative perfusion defect on thallium scan or negative treadmill test)

Exclusion Criteria:

1. Planned cardiac surgery (e.g., CABG, valve repair or replacement, or aneurysmectomy) or planned major non-cardiac surgery within the study period

2. Planned performance of PCI or CABG in the target vessel or its branches containing the index

3. Evidence of congestive heart failure, or left ventricular ejection fraction < 40%

4. Stroke or resuscitated sudden death in the past 6 months

5. Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible)

6. A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer

7. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study

8. Significant renal disease manifested by serum creatinine > 1.5 mg/dL

9. Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 3 times upper limit of normal)

10. Active hepatitis B or C or carrier

11. Hypotension (systolic blood pressure <90 mmHg)

12. Patients already taking ACE inhibitors or ARBs

13. Patients with STEMI requiring primary PCI

14. Patients pregnant or breast-feeding or child-bearing potential

15. Patients who are lack of intention for effective contraception

16. Patients with history of previous enrollment into a clinical trials within 3 months

17. Allergic or contraindicated to Angiotensin II antagonists

18. History of any arterial bypass or angioplastic intervention involving the target vessel

19. Luminal narrowing in the left main > 50% by visual inspection of angiogram

20. Visually-estimated angiographic reference segment diameter of <2.75mm or >4.0 mm

21. Presence of thrombus or complex plaque morphology in the target vessel that suggests a high likelihood of distal embolism

22. Severe tortuosity of the target vessel or any other anatomical reasons that the investigator deems

23. Inappropriate for IVUS procedures. Vessel with thrombus (on GS-IVUS), moderate or severe calcification, angulation

24. Culprit vessel in AMI

25. RWMA (Regional Wall Motion Abnormality) or scar tissue in the territory subtended by the studied lesion

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia
• Plaque, Atherosclerotic

Intervention

Drug:
• Fimasartan
60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
• Placebo
60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)

Locations

Country	Name	City	State
Korea, Republic of	Chonnam National University Hospital	Gwangju
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Ulsan University Hospital	Ulsan

Sponsors (3)

Lead Sponsor	Collaborator
Seung-Jung Park	Boryung Pharmaceutical Co., Ltd, CardioVascular Research Foundation, Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in percent necrotic core (NC) volume of plaque by VH (Virtual Histology) in the "target segment" (within deferred vessel)		baseline and 1 year
Secondary	Change of total atheroma volume (TAV) and percent atheroma volume (PAV) of the target segment and the most diseased 10-mm segment (normalized to different segment length) with the largest plaque volume		baseline and 1 year
Secondary	Percent change in minimal lumen area (MLA) in target segment		baseline and 1 year
Secondary	Change of absolute area or percentages (%) of each plaque VH composition (fibrotic, fibrofatty, dense calcium, necrotic core) at minimal lumen area (MLA) and largest necrotic core area within the target segment		baseline and 1 year
Secondary	Change of VH-IVUS (Intra Vascular UltraSound) detected plaque type from baseline		at 1 year
Secondary	Change of percentage (%) of OCT (Optical Coherence Tomography)-defined TCFA (Thin Cap Fibrotic Atheroma) within the target segment from baseline		at 1 year
Secondary	Change of composition of OCT-defined fibrous, fibro-calcific, and lipid-rich plaque within the target segment		baseline and 1 year
Secondary	Change of OCT-defined fibrous cap thickness, the presence of plaque disruption, calcification or intraluminal thrombus within the target segment		baseline and 1 year
Secondary	Change of FFR in target segment from baseline		at 1 year
Secondary	systolic and diastolic blood pressure		at 1 year follow-up
Secondary	Change in high sensitive CRP (C-Reactive Protein)from baseline		at 1 year